Irritable bowel syndrome (IBS) is a highly prevalent disease marked by a significant level of unmet need for safe, efficacious, multisymptom agents. Irritable Bowel Syndrome is a new study published by Decision Resources, Inc., that examines the therapeutic and commercial potential of emerging therapies to treat IBS.
Four new 5-HT modulators will become available over the 1999-2009 forecast period of this study. Controversy surrounds this class because the first 5-HT- modulating agent for IBS, GlaxoSmithKline's alosetron, was withdrawn from the U.S. market in November 2000, and development in all countries has since halted. A large burden of proof now exists for developers of any future 5-HT modulators for IBS to demonstrate beyond a doubt that their product does not have serious or life-threatening side effects. We believe that the emerging 5- HT modulators will overcome this hurdle. We estimate that seven-market IBS sales for this class will reach $683 million in 2009 and account for 59% of the IBS market.
-- The frontrunner among 5-HT4 agonists is tegaserod (Novartis's Zelmac), which was submitted for approval in both the United States and Europe in February 2000 and is in Phase III trials in Japan. Recent trial data suggest that tegaserod produces only mild side effects, even in patients who are contraindicated, and that it will therefore not cause the kind of life-threatening events seen with alosetron. -- Cilansetron, a 5-HT3 antagonist, is being developed by Solvay in the United States and Europe for diarrhea-predominant IBS. Trial data published to date have not shown problematic rates of side effects, and Solvay has issued public statements that cilansetron will not have the same problems as aloestron. If late-stage trials proceed well, cilansetron has the potential to be the first in its class to establish itself in the IBS market. -- Two multiple-5-HT-receptor modulators, Alizyme's renzapride and Eisai 's E-3620, have the potential for use in all subtypes of IBS if these agents' multi-receptor action causes a motility-normalizing effect. Renzapride should be available in all seven major markets by 2009. -- Beyond the 5-HT modulators, we examine three other groups of agents are in development for IBS: gastroprokinetics, tachykinin antagonists, and CCK antagonists.
Irritable Bowel Syndrome offers invaluable market intelligence for pharmaceutical companies competing in the IBS market, and is a part of Mosaic, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,